TY - JOUR T1 - BIOLOGICAL RHYTHMS IN COVID-19 VACCINE EFFECTIVENESS JF - medRxiv DO - 10.1101/2022.10.31.22281719 SP - 2022.10.31.22281719 AU - Guy Hazan AU - Or A. Duek AU - Hillel Alapi AU - Huram Mok AU - Alex Ganninger AU - Elaine Ostendorf AU - Carrie Gierasch AU - Gabriel Chodick AU - David Greenberg AU - Jeffrey A. Haspel Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/11/02/2022.10.31.22281719.abstract N2 - Importance Circadian rhythms affect fundamental immune processes, but how this translates to clinical outcomes like real-world vaccine effectiveness is unclear.Objective To examine associations between Coronavirus Infectious Disease 2019 (COVID-19) vaccination timing and effectiveness.Design, Setting, and Participants Retrospective cohort study of database records from Maccabi Healthcare Services (MHS), a major Israeli Health Maintenance Organization (HMO). We included all individuals over 12 with at least one timestamped vaccine dose and no documented COVID-19 infection prior to completing the initial 2-dose immunization series (n=1,515,754, 99.2% receiving BNT162b2). Database records spanned December 19, 2020, to April 25, 2022, encompassing two spikes in COVID infection dominated by the delta (B.1.617.2) and omicron (B.1.1.529) SARS-CoV-2 variants.Main Outcomes and Measures Outcomes included COVID-19 breakthrough infection and COVID-19 associated emergency department (ED) visits. Our main comparison was between patients vaccinated exclusively during morning hours (8:00-11:59), afternoon (12:00-15:59), or evening hours (16:00-19:59). We employed Cox multivariate regression to adjust for differences in age, sex, and co-morbidities.Results Breakthrough infections differed based on vaccination time, with lowest rates associated with late morning to early afternoon, and highest rates with evening vaccination. Vaccination timing remained significant after adjustment for patient age, sex, and co-morbidities (HR=0.88 afternoon vs. evening, [95% CI 0.87-0.90]). Results were consistent in patients who received the basic two-dose vaccine series and who received booster doses. The relationship between COVID-19 immunization time and breakthrough infection risk was sinusoidal, consistent with a biological rhythm in vaccine effectiveness. Vaccination timing altered breakthrough infection risk by 8.6-25% in our cohort, depending on patient age and dose number. The benefits of daytime vaccination were concentrated in younger and elderly patients. In contrast to breakthrough infections, COVID-19 related ED visits correlated with age and medical comorbidities but not with time of vaccination.Conclusions and Relevance We report a significant association between the time of COVID-19 vaccination and its clinical effectiveness in terms of breakthrough infection. These data have implications for mass vaccination programs.Question Does the time of day patients receive their COVID-19 vaccinations influence their clinical benefit?Findings In this population-level cohort study that included 1,515,754 individuals aged 12 and over, COVID-19 vaccination during the late morning to early afternoon was associated with fewer breakthrough infections compared to other times. Vaccination timing altered breakthrough infection risk by 8.6-25%, depending on patient age and dose number.Meaning Prioritizing children and the elderly for late morning to early afternoon immunization could improve the effectiveness of mass vaccinations against COVID-19, and potentially other infectious diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by NIH R01 HL135846, R01 HL152968, and internal funds from the Washington University School of Medicine, Department of Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Maccabi Healthcare Services ethical committee approved the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesR code for all analyses is available upon request. Pursuant to Maccabi Healthcare Services data sharing policy, individual patient data will not be shared. We provide a full list of outcome variables and clinical covariates for this study in eTables 1 ans 2 of the Supplemement. ER -